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Zusammenfassung 
 
 
 
 
Vetsuisse-Fakultät Universität Zürich 2017 
 
Nadine Schulz 
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        ehuber@vetclinics.uzh.ch 
 
In vivo Charakterisierung der Dynamik von DNA-Schäden und deren Reparatur unter 
Radiotherapie an Hunden als Modell 
 
Die Beobachtung von DNA-Schäden und DNA-Reparatur an durch Radiotherapie 
behandelten Zellen liefert Informationen über deren intrinsische Radiosensitivität. 
Bisher verfügen wir über wenige Informationen über den zeitlichen Ablauf von DNA-
Reparatur in Tumorzellen, die direkt aus Patienten gewonnen wurden. Somit wurden von 
Weichteilsarkomen (n=6) und malignen Melanomen (n=2) von 8 Hunden sowie  
mitbestrahlten Normalgeweben wiederholt Proben vor und nach Radiotherapie entnommen 
und auf die Kinetik von DNA-Schäden und deren Reparatur analysiert. 
Die Resultate wurden  mit einem mathematischen Modell für DNA-Schäden verglichen. Als 
Analysemethoden für die Kinetik der DNA-Schäden und Reparatur fanden der Comet-Assay 
und Immunhistochemie für γH2AX Anwendung. Der prozentuale Anteil von DNA im 
Kometenschweif erreichte sein Maximum 15-60 Minuten nach Bestrahlung mit einem 
schnellen Abfall 120 Minuten nach Bestrahlung. 
Während die basalen γH2AX-foci in Tumorproben von Weichteilsarkomen (n=16), malignen 
Melanomen (n=19), Karzinomen (n=25) und malignen Lymphomen (n=23) sich einzig bei 
den Lymphomen unterschieden, bestätigte die Focibildung von γH2AX nach Bestrahlung die 
Ergebnisse der Comet-Assays. Die in vivo Daten der Sarkome deckten sich gut mit dem 
mathematischen 2-Pathway-Modell, was für die Melanomdaten nicht zutraf.  
Zusammenfassend deutet die Arbeit darauf hin, dass DNA-Schäden und deren Reparatur sich 
mit einer minimalinvasiven Methode im zeitlichen Ablauf untersuchen lassen. 
 
 
Stichwörter: DNA-Schäden, DNA-Reparatur,  γH2AX-Foci, Comet-Assay, Radiotherapie 
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Summary 
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Dynamic in vivo profiling of DNA damage and -repair after radiotherapy using canine 
patients as a model 
 
Monitoring formation and repair of damage in a cell after radiotherapy represents a means to 
provide information on intrinsic radiosensitivity. Little is known about the time course of 
DNA damage response in tumors sampled from individual patients. DNA damage produced 
by therapeutic ionizing radiation with repeated in vivo sampling of canine tumors and co-
irradiated normal tissue were evaluated in 8 dogs with either soft tissue sarcoma (n=6) or 
malignant melanoma (n=2). In vivo results were compared with a dynamic mathematical 
model for DNA damage formation and repair by a 2-pathway model. Kinetics of DNA 
damage and repair were assessed with comet assay and γH2AX immunohistochemistry. The 
%DNA in tail peaked at 15-60 minutes after irradiation with a rapid decrease at 120 minutes. 
While baseline levels of γH2AX-foci in tumor samples from 83 dogs (soft tissue sarcomas 
(n=16), malignant melanomas (n=19), carcinomas (n=25), malignant lymphomas (n=23)) 
only differed in lymphomas, the time courses of γH2AX-foci after therapeutic radiation 
paralleled the findings from the comet assay with a small time delay, with no influences of 
covariates. The evolutionary parameter search revealed a good fit of the 2-pathway model to 
in vivo data for sarcoma, but not for melanoma when fast and slow processes were included. 
We conclude that DNA repair can be quantitatively investigated not only by evaluating initial 
or residual damage, but also by following time courses of individual patients. 
 
 
 
 
 
Keywords: DNA damage repair, γH2AX-foci, comet assay, radiation, 2-pathway repair model 
 
 
 
 
 
5 
 
Dynamic in vivo profiling of DNA damage and -repair after radiotherapy 
using canine patients as a model 
 
Nadine Schulz1, Hassan Chaachouay1, Katarzyna J. Nytko1, Malgorzata Roos2, Rudolf M. 
Füchslin3, Mathias S. Weyland3, Franco Guscetti4, Stephan Scheidegger3, Carla Rohrer Bley1* 
1 Division of Radiation Oncology, Vetsuisse Faculty University of Zurich, CH-8057 Zurich, 
Switzerland 
2 Department of Biostatistics, Epidemiology Biostatistics and Prevention Institute, Faculty of 
Medicine, University of Zurich, CH-8001 Zurich, Switzerland 
3 ZHAW School of Engineering, Zurich University of Applied Sciences, CH-8400 
Winterthur, Switzerland 
4Institute of Veterinary Pathology, Vetsuisse Faculty University of Zurich, CH-8057 Zurich, 
Switzerland 
 
*Corresponding Author 
E-mail: crohrer@vetclinics.uzh.ch 
  
 
 
 
 
 
6 
 
Abstract 
Time resolved data of DNA damage and -repair after radiotherapy elucidates the relation 
between damage, repair and cell survival. While well characterized in vitro, little is known 
about the time course of DNA damage response in tumors sampled from individual patients. 
Kinetics of DNA damage after radiotherapy was assessed from 8 dogs with repeated in vivo 
sampling of tumor and co-irradiated normal tissue with comet assay and γH2AX 
immunohistochemistry. In vivo results were then compared (in silico) with a dynamic 
mathematical model for DNA damage formation and repair by a 2-pathway-model.  
Maximum %DNA in tail was observed at 15-60 minutes after irradiation, with a rapid 
decrease. Time courses of γH2AX-foci paralleled these findings with a small time delay, not 
influenced by covariates. The evolutionary parameter search (based on %DNA in tail) 
revealed a good fit of the 2-pathway-model to in vivo data for sarcoma, but not melanoma 
when fast and slow processes were included. It was possible to follow dynamics of comet tail 
intensity and γH2AX-foci during a course of radiation using a minimally invasive approach, 
and to integrate resulting data into a dynamic mathematical model, hence DNA repair can be 
quantitatively investigated by following time courses of individual patients. 
 
Short title: DNA damage repair after radiotherapy 
Keywords: DNA damage repair, kinetics, γH2AX-foci, comet assay, dog, radiation, 2-
pathway repair model 
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Introduction 
Monitoring the formation of damage in a cell after radiotherapy (RT) and the evaluation of 
DNA repair markers may be a means to provide information on intrinsic radiosensitivity and 
radio-responsiveness [1-3]. Ionizing radiation used as a cancer treatment relies on the 
formation of direct DNA damage or on creating sufficient cellular damage leading to double 
strand breaks (DSBs), which in turn trigger the activation of cellular death pathways. Upon 
damage, the cells activate a DNA-damage response, consisting of various pathways which 
will sense the extent of damage and induce an effector pathway either leading to cell death, 
cell cycle arrest or DNA damage repair [4]. DNA damage detection from patient samples has 
been performed for various tumor groups irradiated ex vivo, resulting in robust correlations 
with radio-responsiveness as known from clinical behavior [2,5]. Furthermore, monitoring the 
responses towards damage formation and repair from individual tumors may offer a legitimate 
chance to monitor cancer treatment and even a possibility to predict clinical response to 
treatment [6,7]. This is thought to hold true even in spite of high inter-tumoral and inter-
patient heterogeneity that is to be expected from patient samples [6,7].  
While the time courses in responses to different DNA damaging agents have been 
characterized well in cultured tumor cells in vitro, little is known about the time course of 
DNA damage response in tumor and normal tissues sampled from individual tumor patients 
[2,5,6,8-10]. Specifically, actual time courses from patients undergoing radiation therapy are 
lacking. Time resolved data of DNA damage formation and repair can be used to elucidate the 
relation between DNA damage formation, repair and cell survival. It can be expected that e.g. 
a higher amount of DNA fragments in the tail of a comet assay or residual γH2AX-foci are an 
indication for a higher initial radiosensitivity.  
The aim of this study was twofold: first, we wanted to use the minimally invasive sampling 
techniques (fine needle aspirates (FNAs)) and small biopsies for repeated in vivo patient 
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sampling and subsequent biostatistically quantify the amounts and time courses of DNA 
damage produced by therapeutic ionizing radiation. As a model, sampling was performed in 
canine tumor tissue as well as of co-irradiated normal tissue from patients undergoing 
treatment. In order to study DNA damage in samples of low cellularity, the comet assay [11-
13] was used to detect DNA breaks at the level of individual cells in a rapid, sensitive and 
simple manner. To validate our data from the alkaline comet assay and to gain additional 
information, staining of phosphorylated H2AX (γH2AX) foci was performed in parallel at 
several time-points after treatment with RT [14]. Second, the clinical in vivo results were then 
compared (in silico) with a dynamic mathematical model for DNA damage formation and 
repair by a 2-pathway model. With the postulation of a second order decay (removal) of DNA 
fragments in the comet tail, the goal of the introduction of clinical patient data into such a 
tumor-patient model is to identify characteristic kinetic constants and delay times [15].  
By integrating the repeated, minimally invasive in vivo measurements of clinical patients 
treated with RT into a mathematical model based data analysis, the potential of computer 
simulation of such time courses was strengthened. This in turn will allow its future use in a 
more comprehensive framework for the interpretation of obtained patient data and for 
guidance of therapy.   
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Results 
Treatment courses were followed analyzing the comet tails (% of DNA in tail) at the chosen 
time-points at the first and before the second fraction of radiotherapy. In parallel to the DNA 
content in comet tails, γH2AX foci at the chosen time-points were evaluated in tumor and co-
irradiated normal tissue and the influences of covariates are described. The resulting data was 
used to compute the median DNA fragments at every time point in silico. Additionally, by 
evaluating a set of untreated tumor samples, a rough quantification of the basal levels of 
γH2AX foci in canine tumors was established. 
 
Patient, tumor and radiation dose characteristics  
Complete datasets of 8 patients were available for repeated sampling. From the 8 dogs, 4 were 
female (2 spayed) and 4 were neutered males. The dogs were of various pure (n=5) and mixed 
breeds (n=3) and a total of 5 breeds were represented. The ages ranged from 8.17-13.67 years 
with a mean of 11.28 (± 1.63) years. The weight ranged from 11.00-38.50 kg, with a mean of 
23.73 (± 8.51) kg. Tumor volumes ranged from 9.24 to 97.91 cm3 with a mean of 27.43 cm3 
(± 29.33). Of the 8 cases, 6 tumors (75%) were histologically described as canine soft tissue 
sarcoma and 2 (25%) as malignant oral melanoma. Radiation therapy was applied in 5x6 Gy 
over 2.5 weeks in 7 patients and in 4x8 Gy in one patient (with malignant melanoma). 
 
Comet assay: tail intensities (% DNA in tail) after radiotherapy in tumor 
samples  
Compared to pre-treatment (T0), the measured %DNA tail peaked at 15 to 60 minutes after 
RT. The maximum %DNA in tail was observed at 15-60 minutes after irradiation, with a 
rapid decrease at 120 minutes. The median tail intensities differed significantly up to and 
including the 60 minutes post treatment time point (p ≤ 0.001). Afterwards, a rapid decrease 
10 
 
was found, already after 120 and 360 minutes, as well as before the second fraction, where 
median tail intensity was not significantly different from T0 anymore. (Table 1 and Additional 
file 2) 
 
Table 1: Differences of median tail intensity (% DNA in tail), comet assay (%; 95%CI). 
T0, T15, T30, etc. indicate the time-points in minutes after completion of radiation treatment  
Time-points 
Difference of % DNA in tail  
(95%CI) 
p-value 
T0 → T15 10.80 (6.56 – 15.04) p=0.001 
T0 → T30 11.24 (6.38 – 16.10) p=0.001 
T0 → T60 7.11 (4.52 – 9.71) p<0.001 
T0 → T120 2.47 (-1.41 – 6.36) p=0.172 
T0 → T360 1.24 (-0.86 – 3.33) p=0.185 
T0 → Tbefore 2nd fraction 1.56 (-0.87 – 3.99) p=0.168 
 
 
γH2AX: number of positive cells and of foci per cell after radiotherapy in tumor 
samples  
Samples from three time-points (T0, T30, T360) of the included patients were analyzed for the 
number of positive cells (%), as well as foci/cell. Both the amounts of positive cells as well as 
the numbers of foci per cell at T30  and T360 were significantly different from those at T0 
(p<0.001 for positive cells; p=0.002 for foci/cell). As shown in Tables 2, both values had 
returned to baseline before the second fraction. The concurrently sampled co-irradiated 
normal tissue from the tumor patients followed the same pattern regarding the disappearance 
of foci (Fig 1). 
11 
 
 
Table 2a: Positive staining (%) for γH2AX-foci. T0, T30, T360, etc. indicate the time-points 
in minutes after completion of radiation treatment
 
 
Time-points 
Median γH2AX positive cells  
(%; 95%CI) 
p-value, 
compared to T0 
T0 24.35  
T30 86.95 (73.15 – 100.74) p<0.001 
T360 79.50 (63.31 – 95.68) p<0.001 
Tbefore 2nd fraction 22.5 (6.58 – 38.13) p=0.764 
 
Table 2b: Number of γH2AX-foci per positive cell. T0, T30, T360, etc. indicate the time-
points in minutes after completion of radiation treatment
 
 
Time-points 
Median γH2AX-foci per nucleus 
(95%CI) 
p-value, 
compared to T0 
T0 2.41  
T30 10.49 (8.44 –2.54) p<0.001 
T360 5.00 (3.88 – 6.12) p=0.002 
Tbefore 2nd fraction 2.00 (1.56 – 2.44) p=0.163 
 
Figure 1: Time course of γH2AX immunohistochemical labeling in normal epithelium, 
soft tissue sarcoma and malignant melanoma. All tissues show low γH2AX reactivity 
before radiotherapy, high numbers of γH2AX positive cells and foci per cell at 30 minutes 
after radiotherapy and a decrease of the respective numbers at 360 minutes after radiotherapy. 
(RT = radiotherapy; bars: overview 20 μm, insert 15 μm)   
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Covariate analysis 
Due to the time dependence, a linear mixed model approach was applied to detect 
associations between the median tail intensity, median positive cells, median foci/cell and 
covariates such as age, gender, tumor volume and cancer type. No influence of the covariates 
or the different fractions of serial measurement was detected. 
 
Baseline levels of γH2AX in tumor biopsy samples of various histologies 
Samples of various histologies (soft tissue sarcomas (n=16), malignant melanomas (n=19), 
carcinomas (n= 25) and malignant lymphomas (n=23)) were taken from patients undergoing 
surgical tumor removal for diagnostic or treatment purposes at the clinic (see Table 3 for 
patient-specific details). While the sampling groups did not vary in gender (p=0.186), age 
(p=0.014, malignant lymphoma younger than malignant melanoma patients) and weight 
(p=0.016, soft tissue sarcomas heavier than malignant melanoma and carcinomas patients) 
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showed some (clinically non-relevant) differences. Histologically, the malignant lymphoma 
tumor group had significantly higher values in foci/cell (p<0.001), compared to the 
population with soft tissue sarcoma, malignant melanoma or carcinomas (Fig 2). For positive 
cells (p=0.014) the malignant lymphoma tumor group had significantly higher values than the 
population with soft tissue sarcoma. 
Table 3: Patient specific details for baseline values of γH2AX foci. f= female, fs = female 
spayed, m = male, mn = male neutered 
 Age [years] 
mean (SD; 
range) 
Weight [kg] 
mean (SD; 
range) 
Gender 
Median 
positive cells 
(%) 
95% CI p-
value 
Median 
foci / 
tumor 
95% CI p-
value 
Overall (n=83) 
9.89 
(±2.92;  
1.00-15.00) 
23.70 
(±10.90; 
3.60-55.00) 
f=14  
fs=27 
m=19 
mn=23 
20.72 21.88-24.29 0.014 2.50 
2.40-
2.90 
<0.00
1 
Soft tissue 
sarcoma (n=16) 
9.74 
(±1.80;  
5.92-12.83 
30.40 
(±9.88; 
14.20-50.70) 
f=3  
fs=7 
m=3 
mn=3 
13.41 7.42-20.59  2.00 
1.50-
2.47  
Malignant 
melanoma 
(n=19) 
11.71 
(±2.59; 
6.00-15.00) 
19.24 
(±8.78; 
3.60-30.50) 
f=2 
fs=4 
m=7 
mn=6 
15.35 12.25-28.22  2.50 
2.14-
2.99  
Carcinoma 
(n=25) 
9.48 
(±3.33; 
1.00-15.00) 
20.79 
(±10.23; 
4.50-35.50) 
f=6 
fs=6 
m=8 
mn=5 
18.12 14.55-28.67  2.00 
2.03-
2.81  
Malignant 
lymphoma 
(n=23) 
8.94 
(±2.67; 
3.58-13.75) 
25.88 
(±11.04; 
9.00-55.00) 
f=3 
fs=10 
m=1 
mn=9 
31.30 24.72-34.93  3.00 
2.87-
4.04  
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Figure 2: Examples of baseline levels γH2AX immunohistochemical labeling in indicated 
tumor types. (Bars: overview 20 μm, insert 15 μm) 
 
 
Quantification of the time course of DNA damage and –repair using novel 
mathematical modeling 
The evolutionary parameter search (based on the median % DNA in tail) reveals a good fit to 
the in vivo data for the sarcoma when both processes (fast and slow) are included. Since in this 
data no shoulder is visible (neither in the average of 3 fractions nor in of the fractions), we 
tested the case when only the fast pathway is activated. This fit has a larger error (Table 4) but 
in relation to the scatter of the data (Fig 3a) it covers the experimental results fairly well. The 
melanoma data exhibit a shoulder, which is not very pronounced in the average of all fractions 
(Fig 3b), but is well visible in the comet data of the second fraction (Fig 3c and 3d). As shown 
in Fig 3c, the evolutionary parameter search fails to find parameters that represent the shoulder.  
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Table 4: Parameter sets of the bio-mathematical model for sarcoma and melanoma. For 
the final repair step, second order kinetics is assumed and the data is given in % DNA. The 
numbers given in parentheses in column 1 (sarcoma, average 3 fractions) are for a fit of the 
full model; for the other values in that column, it was assumed that the comet data are 
dominated by the fast process, since no shoulder is visible in the data. 
Parameter 
Sarcoma, 
average over  
3 fractions 
Melanoma, 
average over  
2 fractions 
Melanoma, 2nd 
fraction, best fit 
Melanoma, 2nd 
fraction, hand-
picked solution 
cleavk  / min-1 
 
1.93 (1.96 ) 1.93 (1.96 ) 2.69 3.56 
0, fastk  / min-
1 
 
13.93 10−⋅   
( 11.59 10−⋅ ) 
13.93 10−⋅   
( 11.59 10−⋅ ) 
39.69 10−⋅
 
18.75 10−⋅
 
1, fastk  / min-1 
 
22.92 10−⋅   
( 23.44 10−⋅ ) 
22.92 10−⋅   
( 23.44 10−⋅ ) 
32.13 10−⋅
 
25.87 10 −⋅
 
2, fastk  / min-
1 
 
21.00 10−⋅   
( 39.01 10−⋅ ) 
21.00 10−⋅   
( 39.01 10−⋅ ) 
12.82 10⋅
 
12.74 10⋅
 
0,slowk  / min-
1 
 
- ( 33.22 10−⋅ ) ( 33.22 10−⋅ ) 13.00 10⋅  17.59 10−⋅  
1,slowk  / min-
1 
 
- ( 31.01 10−⋅ ) ( 31.01 10−⋅ ) 21.57 10−⋅  37.48 10−⋅  
2,slowk  / min-
1 
 
- ( 21.23 10⋅ ) ( 21.23 10⋅ ) 6.38  14.22 10⋅  
.r slowt  / min 
 
- (7.07) (7.07) 1.03 15.34 10⋅  
,r fastt / min 
 
11.28 10⋅   
( 11.09 10⋅ ) 
11.28 10⋅   
( 11.09 10⋅ ) 
16.98 10−⋅  6.38 
16 
 
nb  / % 
DNA 
 
4.23 (4.09) 4.23 (4.09) 6.93 5.28 
Error of fit
 
1.20 (1.03) 1.20 (1.03) 11.50 10⋅  11.63 10⋅  
 
Figure 3: Time resolved comet data fitted by the bio-mathematical 2-pathway model. (a) 
Average of median % DNA in tail over 3 fractions for sarcoma cells, with only the fast repair 
pathway activated; (b) average of median % DNA in tail over 3 fractions for melanoma cells; 
(c) median % DNA in tail for 2nd fraction for melanoma cells with the parameters yielding the 
smallest error of fit; (d) median % DNA in tail for 2nd fraction for melanoma cells with a 
hand-picked solution representing the shoulder well at the expense of a larger error of fit; the 
error bars indicate the upper and lower quartile. 
 
 
A B 
C D 
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One of the possible reasons for this discrepancy between the in vivo data and the data generated 
by the model with the best fit according to the parameter search is as follows: The initial value 
(9.0% DNAin tail) before radiation is higher than the value at 360 min (4.6 % DNA in tail). 
Therefore, there are two baselines, one before and one after radiation. Since the model assumes 
one single baseline value, the error of fit remains large. As shown in Fig 4d, a hand-picked set 
of parameters does reproduce the shoulder at the expense of a slightly larger error of fit. The 
different parameter search runs reveal for some parameter varying values (especially ) 
whereas other values seem to evolve to stable values (e.g. , ). 
In diagrams in Fig 4, the inter-quartile distances indicate the inhomogeneity of the cells. 
Especially for melanoma cells, first and second fractions differ remarkably, whereas for 
sarcoma, the three fractions exhibit more or less the same shape of the curve (as shown in Fig. 
4a, after a rise follows a decay as a result of first and second order processes). 
 
 
 
 
 
 
 
 
 
 
2, fastk
cleavk ,r fastt
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Discussion  
Up to date, to the author’s knowledge, no DNA damage induction, or repair time-courses 
have been described from patients undergoing radiation therapy. Hence, very little is known 
about the amount of actual DNA damage and the kinetics of repair in tumors in vivo, as well 
as of normal tissues under antineoplastic treatment. Herein, we used repeated samples from 
dogs with primary tumors undergoing therapeutic radiation therapy. Spontaneous tumors in 
companion animals like dogs have been described to offer a unique opportunity as a model 
for human cancer biology and translational clinical research [15,16]. In contrast to most 
murine tumor xenograft studies, cancers in dogs arise over the background of an intact 
immune system and present many features like histological appearance, tumor genetics, 
molecular targets, biological behavior and response to conventional therapies, as well as inter-
patient tumoral heterogeneity common to humans [15]. Moreover, in many terms a canine 
model will even serve better than the murine one to study DDR and its defects in vivo, as in 
rodents certain repair pathways seem to be less active in comparison to the human 
mechanisms, displaying a potentially a different emphasis and hierarchy of DNA repair 
pathways [17].  
The intrinsic radiosensitivity of the tumor cells is a major determinant of the treatment 
response and outcome and correlates with patient’s prognosis [18]. As summarized by 
McKenna et al., also the comet assay technique has been used in a wide range of human 
tumor cell lines as well as tissue biopsies and has shown predictive information value of the 
individual’s sensitivity towards DNA damaging agents [13].  In this study, the kinetic median 
tail intensity (% DNA in tail) showed a fast time-course, with no significant remaining 
differences in tail intensity after 120 minutes post radiation for both soft tissue sarcoma as 
well as malignant melanoma samples. The alkaline comet assay was chosen because it is 
capable of detecting and quantifying effects of low, yet clinically relevant radiation doses of 
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0-6 Gy. Under alkaline conditions, DNA is denatured and both single strand breaks as well as 
double strand breaks are measured in the tail. In samples of human bladder cancer tissue 
irradiated ex vivo, evaluation for radiation induced DNA damage levels were measured by this 
method and the extent of comet formation was found to correlate with cell killing. 
Furthermore, in this patient cohort, reduced DNA damage sensitivity was associated with 
poorer treatment outcomes, implying a clinical predictive potential for treatment-induced 
DNA damage detection with the alkaline comet assay in certain tumors [6,19,20]. However, 
the alkaline comet assays is detecting both, double - and single strand breaks [21,22]. Hence, 
this assay is also detecting damage not necessarily directly responsible for cell death, as 
lethality is most frequently observed after non- or miss-repaired DSB. The neutral comet 
assay on the other hand can be modified to detect double strand breaks only, but this requires 
doses of radiation far higher than the clinically relevant ones. As a general advantage, comet 
assay is a relatively inexpensive, simple and fast technique that can be carried out on single-
cell suspensions, requiring a small number of cells [13]. This in contrast to the more widely 
used clonogenic cell survival assay, which measures a surviving fraction of tumor cells after a 
given clinically relevant dose, but takes a number of weeks to be completed, e.g. to obtain the 
results of clonogenicity of the tumor cells [23]. Showing a strong correlation between the 
methods of clonogenic survival and alkaline comet assay at clinically relevant doses in tumor 
cell lines, these measurements of initial as well as residual DNA damage can probably be 
used to predict radiation sensitivity in patient derived tumor cells as well [19,20,24].  
Prior work including in vivo mouse assays with various cell lines of head and neck carcinoma, 
as well as in ex vivo assays using different tumor types from patients has documented radio-
responsiveness in sensitive and resistant tumor types to be represented by residual γH2AX-
foci [1,2,5]. After antineoplastic treatment, the initiation of DNA repair by the two major 
responsible pathways is triggered by the phosphorylation of the histone protein H2AX that 
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leads to formation of γH2AX-molecules at the site of the DSB [4,25,26]. Upon repair, the 
γH2AX-foci will disappear over a time course, mostly in concert with DSB rejoining, but it is 
also suggested that a part of foci removal depends on subsequent steps of DSB rejoining 
[25,27]. Several reports describe the induction and decline of γH2AX foci in vitro [28-31], 
and also in cancer and normal tissues irradiated in/ex vivo [2,5,32,33]. It has been reported 
that γH2AX foci number in bone marrow cells of mice irradiated with 4 Gy peaked at 1 hour 
after treatment and decreased to baseline already after 4 hours, while in contrast γH2AX foci 
were still present in irradiated spermatocytes and round spermatid after 48 hours [33]. The 
kinetics of foci induction and disappearance depends on dose of ionizing radiation, intrinsic 
cellular radiosensitivity, cell cycle position and DNA content, the baseline levels of γH2AX 
and furthermore on microenvironmental conditions such as tissue oxygen concentration [34]. 
In accordance with our observations there is a general pattern of acute increase right after 
irradiation (5-30 minutes) with decrease between 0.5-24 hours after irradiation, depending on 
the type of tissue or cells [35]. As a common finding in cultured cancer cells as well as in 
malignant human tumors of different origins, also untreated canine cancers contain elevated 
levels of spontaneous γH2AX-foci, which are thought to represent inherent genomic 
instability [30]. The overall median number of 2.5 foci per cell found herein, ranging from 
1.5-2.5 in soft tissue sarcomas to 2.9-4 in malignant lymphoma (e.g. high-grade non-
Hodgkin’s lymphoma) was within the range of 1-20 foci per cell described in human cancers 
and various canine cell lines [30,36]. In line with our data, recent reports show continuous 
activation of DNA-repair pathways and constitutive expression of γH2AX in human diffuse 
large B-cell lymphoma [28,37].  
The bio-mathematical model chosen can be used to describe the comet assay derived-data for 
sarcoma, even when only one pathway is assumed to be activated. For melanoma data, the 
different baseline prior and after radiation caused problems for fitting: the lower baseline for 
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DNA fragments in tail after radiation may be a result of induced repair, which is not (yet) 
implemented in the bio-mathematical model. The evolutionary parameter search seems to be 
very sensitive to the constraints set for the optimization runs. In contrast to other models 
[38,39], the 2-pathway model used in this work summarizes the different process steps in a 
repair pathway by a delayed process. The consequence of this approach is on one hand a 
reduction of parameters but on the other hand a model containing Delay Differential 
Equations (DDE) which makes the evolutionary parameter search more difficult. The 
interpretation of the parameter values derived by fitting the comet data in this work remains 
challenging at this point. A better aggregation of the parameter values may be reached (1) by 
fitting data from more fractions and tumors and (2) by improving time resolution (especially 
time point 240 minutes and more time points in the shoulder region 10 - 120 minutes). The 
comparison with time-resolved γH2AX foci signals may be another option: however, the 
decay of γH2AX foci is slower (possibly due to the remaining of attached ATM after DNA 
strands are glued together) and therefore could mask the real dynamics of repair (e.g. the time 
course of DSB elimination)[40]. For gaining deeper insight into the full dynamics of the 
involved repair processes, dose-rate dependent data would be needed, representing a general 
limitation of using material from patients with spontaneous tumors. A full thorough 
characterization is more difficult compared to well-defined cell lines treated in vitro. 
In this study, after a first data screening, we decided to group the data of sarcoma and 
melanoma patients for the initial modeling. One has to keep in mind that differences in 
intrinsic radiosensitivity in tumors of the same histological origin exist and can be remarkable 
[30,41,42]. As a further general limitation of this in vivo approach, minimally invasive and 
repetitive tumor sampling bears the risk of a mis-representation of the whole tumor due to 
intra-tumoral heterogeneity in the extent and distribution of malignancy, stromal reaction, 
inflammatory cells, necrosis and hypoxia. The sampling heterogeneity with fine needle 
22 
 
aspirates and subsequent comet assay might falsely reflect the intrinsic radiosensitivity or 
repair capacity, and the manipulation of single tumor cells and tissues can induce further 
sampling error. Sanguineous contamination may occur, leading to measurement errors with 
very high DNA intensities in the comet tail, an intensity error that can also be produced by 
early apoptotic cells [13,43]. Concurrent microscopic evaluations of FNA samples are 
recommended to assess the representativeness of a sample. These limitations however, reflect 
the clinical situation in any predictive testing for individual patients with the goal of 
personalized medicine and cannot be completely circumvented. However, in patient sample 
dependent mathematical data modeling they can be in part attenuated by choosing a high time 
resolution and large individual sample size.  
At early time-points after RT, quantification of γH2AX foci was impaired due to foci overlap. 
However, this is a phenomenon also problematic for immunofluorescent staining and 
computerized quantification. In our evaluation, samples with foci numbers higher than 10 
were adjusted as “25 foci” per cell. This was the case in samples taken 30 minutes and 6 
hours after irradiation. Furthermore, there is an ongoing debate in the literature regarding 
what should be considered as focus, which is also subdued to certain subjectivity in manual 
scoring [44].  
In conclusion, we confirm the clinical feasibility of repeated in vivo minimally invasive 
sampling with FNA as well as small biopsies in order to quantify the amounts and time 
courses of DNA damage produced by therapeutic RT. Both, dynamics of comet tail intensity 
and γH2AX-foci could be tracked during a course of radiation and the resulting data could be 
integrated into a dynamic mathematical model for DNA damage formation and repair by a 2-
pathway model. By evaluating not only initial or residual DNA damage, but following a time 
course of an individual patient, DNA repair can be quantitatively described. The inclusion of 
individual patient measurement data into mathematical based model analysis can indicate the 
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types of repair predominating in this patient, leading to information that could impact the 
future practice of radiation therapy towards a personalized approach. 
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Materials and Methods  
The current investigation involved samples of canine tumor patients with various types of 
cancers. In repeated samples from patients treated with RT, DNA damage formation and 
repair was assessed with comet assay (an assay used to investigate DNA damage in human 
biomonitoring and genotoxicology) [11-13] and γH2AX immunohistochemistry (representing 
an early event after double-strand break formation) [14,45] at defined time points. The 
resulting findings were then integrated into the bio-mathematical repair-pathway model in 
order to perform a model-based analysis of comet data. Additionally, biopsies of various 
tumors were screened with immunohistochemistry for the amount of pre-treatment γH2AX 
levels in order to define a baseline of DNA damage in canine tumors.  
 
Patients and sampling procedures 
Dogs presented to the Division of Radiation Oncology, Vetsuisse Faculty, University of 
Zurich, Switzerland for treatment of bulky malignant tumors between March 2014 and 
December 2015 were included into the study. Each dog had a clinical work up (tumor staging) 
as appropriate to the type of presenting disease. Written owner’s consent was obtained for 
invasive sampling in this study. This study was carried out in strict accordance with the 
recommendations and the protocol approved by the Animal Ethics Council of the Canton of 
Zurich, Switzerland (Permit Numbers: 180/2011 and ZH108/15). All invasive sampling 
procedures were performed under anesthesia, and all efforts were made to minimize suffering. 
In addition, in order to investigate the basal level of γH2AX, a series of tumor biopsy samples 
of various histologies (soft tissue sarcomas, malignant melanomas, carcinomas and 
lymphomas) were taken from patients undergoing surgical tumor removal for diagnostic or 
treatment purposes at the clinic.  
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For comet assay analysis, tumor cells were collected with a minimally invasive method using 
fine-needle aspiration (FNA): Sampling was performed with a 5 ml syringe attached to a 22-
gauge needle as described before [46]. The aspirated volume of 10 µl was immediately mixed 
with a freezing solution of 440 µl FCS and 50 µl DMSO in pre-cooled cryotubes. Cryotubes 
were stored at -80°C until comet assay was performed. FNA samples from the tumor site 
were taken in duplicates 15 minutes before RT and 15, 30, 60, 120 minutes and 6 hours after 
RT during the first and second fraction of radiotherapy. 
Tumor biopsies were collected using 12-gauge Bard® Biopty-Cut® Disposable Core Biopsy 
Needles, and normal, co-irradiated tissue was sampled with 4 mm punches. Tissue was fixed 
for 24 h in 10% buffered formalin and embedded into paraffin wax by routine methods. 
Samples were taken 15 minutes before, 30 minutes and 6 hours after RT treatment.  
 
Treatment 
Radiation was delivered with a 6 megavolt (MV) linear accelerator (Clinac iX, Varian, Palo 
Alto, USA) using either photons or electrons, depending on tumor size and location. 
Treatment planning was performed on the basis of CT for photon plans or by hand calculation 
for electron plans. During treatment, dogs were under general anesthesia using propofol for 
induction- and sevoflurane for maintenance of anesthesia, immobilized in an individually 
shaped vacuum cushion and if required, additionally equipped with a custom-made bite block. 
The recommendations for specifying dose and volumes as proposed for veterinary medicine 
were adhered to as proposed in the corresponding literature. The prescribed dose was 30 Gy, 
delivered in 5 fractions of 6 Gy applied twice per week, resulting in an overall treatment time 
of 2.5 weeks [47-49].  
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Alkaline Comet Assay 
After thawing, the FNA samples were mixed with 9 ml of ice-cold PBS and centrifuged for 
10 min (1500 rpm, 4°C). The pellet was resuspended in 100 µl of ice-cold PBS. A volume 
corresponding to approximately 170’000 cells was mixed with 90 µl of agarose (1% LMPA in 
PBS, 37°C). Subsequently, 25 µl of agarose-cell solution was pipetted onto 20-well slides 
(Trevigen) in duplicate. The loaded slides were then placed at 4°C for 5 min to allow agarose 
polymerization, and subsequently placed in lysis buffer for 1 h at 4°C, followed by incubation 
twice in ice-cold alkaline electrophoresis solution (pH>13.0) for 10 min at 4°C in the dark. 
After electrophoresis (300 mA, 15 - 20 min), the slides were incubated twice for 10 min in 
dH2O at room temperature followed by incubation in 70% ethanol for 5 min at room 
temperature in the dark. After complete drying, 70 µl of diluted SYBR-Green (1:10 000 in 
TE, pH8) was pipetted on every well and the slides were incubated for 15 min in the dark. 
The slides were washed twice for 10 min in dH2O at room temperature. To provide a 
quantitative analysis of obtained comets (% DNA in tail, tail intensity), the COMET IV® 
scoring system was used.   
 
γH2AX immunohistochemistry 
Information about antibodies, pretreatment, incubation conditions and visualization are 
reported in Table 5. For immunohistochemical staining a Dako Autostainer (Dako, CH-6341 
Baar) was used. Three µm sections were mounted on positively charged slides (Superfrost 
Plus), dried overnight at 37°C, deparaffinized, rehydrated and immersed for 10 min in 10% 
hydrogen peroxide to block endogenous peroxidase activity. Antibody diluent (S2022) and 
wash buffer (S3006) from Dako were used. Negative controls were done omitting the primary 
antibody. 
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Table 5: Antibodies and incubation conditions. Primary antibody, treatment and incubation 
conditions, *HIER= heat-induced epitope retrieval, carried out in a steamer (Pascal S2800, 
Dako) 
Antigen Vendor Antibody 
Type 
Catalogue 
no. / Clone 
Dilution, 
Incubation 
Conditions 
Pre-
treatment 
Visualsation 
Method 
Positive 
Control  
γH2AX 
Ser 139 
Millipore mouse mAb, 
IgG1 
05-
0636/clone 
JBW301 
1:200, 1.3h, 
room 
temperature 
HIER*, 20 
min 98°C, 
citrate 
buffer pH 
6.0 
Envision Kit 
(Dako) 
Irradiated 
canine 
tumor tissue 
 
The quantification of γH2AX positively stained cells and γH2AX foci was performed by 
manual counting by one investigator (NS), after reaching internal consensus on the procedure. 
The tumor slides were scanned and analyzed with NanoZoomer 2.0-HT scanscope 
(Hamamatsu, CH-4500 Solothurn) and visualized using the NDP.view2 software 
(Hamamatsu). For each tumor 10 fields of identical size (50x magnification) were set 
randomly, but dispersed over non-necrotic tumor areas. Furthermore, in each tumor the 
number of γH2AX foci were counted in the nuclei of 300 cells. 
 
Bio-mathematical modeling 
For the bio-mathematical model, the following assumptions were made: DNA breaks can be 
processed by (1) a fast repair pathway reflecting Non-Homologues End-Joining (NHEJ) for 
DSB or SSB-repair by PARP-1/XRCC1/DNA repair module (which may be also involved in 
the DSB repair by the B-NHEJ backup pathway [50]) or by (2) a slower repair pathway 
(Homologous Recombination (HR) for DSB). Since SSB becomes also observable in an 
alkaline comet assay, it can be expected that DNA-fragments produced by direct DSB will be 
flanked by those initially produced by SSB. At this point it is not possible to relate a specific 
repair pathway to the processes (1) or (2). The decision to start with only two pathway (fast 
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and slow) was based on a preliminary analysis of the comet data from melanoma and sarcoma 
(data not shown): The time resolved amount of DNA-fragments in the comet tail exhibits 1-2 
shoulders indicating two different pathways with different repair speed. In Fig 4, a flow chart 
for the 2-pathway model is shown: DNA damages (number ; including SSB and DSB) are 
produced with an induction rate proportional to the dose rate R ( ;  is a 
cleavage constant). Since there is a large number of remaining potential target sites (DNA 
fragments in tail typically below 25%), it is assumed that there is no saturation effect. It has to 
be pointed out here that this is a simplistic approach for fragment generation. Since a 
fragment will be cut out of a DNA strand by 2 hits, one would expect an additional 
dependence of the absorbed dose D at the corresponding time t: . In 
addition, pre-existing, non-radiation induced breaks can lead to the liberation of a fragment, 
when a second, radiation-induced break will occur. This process is then, as initially assumed, 
simply proportional to the dose rate. Both possibilities combined will yield: 
, where  is a dose-equivalent for pre-existing, not-radiation induced 
breaks. Simulations with the different models and varying parameter values for resulted 
only in different values for without significant impact on the terminal course of the 
number of fragments in the tail. Since the number of data points is limited and experiments 
were performed at only one dose rate, we decided to use the simplest approach for fragment 
generation in this study.    
 
Figure 4: Process flow chart for the 2-pathway model. Primary damages ( 0n ) are detected 
by one of the two repair pathways and then transformed to damages prepared for the fast (
) or slow ( ) pathway (by a first order kinetics). The damages are further processed 
and prepared for end-joining (or in case of HR, homology search). Processed DNA fragments 
0n
0 / cleavdn dt k R= cleavk
0 / cleavdn dt k R D= ⋅
0 / ( )cleavdn dt k R Dε= ⋅ − ε
ε
cleavk
1, fastn 1,slown
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(  and ) fade away by the final repair step (second order kinetics). The full set of 
equations of the mathematical model is given in additional file 1.   
 
 
The primary damages ( ) can be detected by one of the two repair pathways and then 
transformed to damages prepared for the fast ( ) or the slow ( ) pathway. For this 
process, first order kinetics is assumed. After detection by a repair-pathway, the damages will 
be processed and prepared for end-joining (or in case of HR, homology search). The amount 
(number) of processed damages is denoted by  and  respectively. It is further 
assumed that all types of damages ( , , , , ) can be transported by 
electrophoresis and are therefore visible in the comet tail. Free DNA fragments fade away by 
the final repair process step, which is described by second order kinetics in the model since 
two fragments are joint together. The full set of equations of the mathematical model and 
parameter values is given in additional file 1. 
For the model-based analysis, the median values of % DNA fragments in comet tail have been 
calculated. To determine the parameter values in the model, an evolutionary optimization 
algorithm using a gradient search method was applied [39].  
2, fastn 2,slown
0n
1, fastn 1,slown
2, fastn 2,slown
0n 1, fastn 1,slown 2, fastn 2,slown
30 
 
Statistical methods 
Data were coded in Excel and analyzed with SPSS version 21. Descriptive statistics such as 
means, standard deviations, medians, interquartile ranges (IQR) together with corresponding 
95% confidence intervals (95% CI) were computed. The non-parametric Spearman 
correlations for associations between two continuous variables were computed. Due to the 
time dependence a linear mixed model approach was applied to detect associations between 
the comet median tail intensity in % (0, 15, 30, 60, 120, 360 minutes after RT and compared 
to the beginning of the next fraction), median γH2AX positive stained cells in %, median 
number of γH2AX foci per cell (0, 30, 360 minutes after RT and compared to the beginning 
of the next fraction) adjusted for the following predictors: age, gender, tumor volume and 
histological group. 
For the analysis of the baseline levels of γH2AX in tumor biopsy samples of various 
histologies the Kolmogorov-Smirnov test was applied to check the correctness of normality 
assumption of the median γH2AX positive stained cells in % and median number of γH2AX 
foci per cell. The one-way ANOVA together with the Scheffé post-hoc test approach was 
taken to investigate differences in primary outcomes of median γH2AX positive stained cells 
in % and median number of γH2AX foci in the nucleus, age and weight with respect to 
diagnostic code. The association between the diagnostic code and gender was checked with 
the Chi2-test.  
Results of statistical analysis with p-value <5% were interpreted as statistically significant. 
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Supporting Information 
Additional File 1: Bio-mathematical 2-pathway model. The initial number of fragments 
0 0 ( )n n t=
 is assumed to be produced proportional to the dose rate R and a cleavage constant 
cleavk
. The number of fragments 1, 1,
( )fast fastn n t=
 represents fragments recruited for the fast 
repair-pathway by a first order kinetics process with the speed constant 0, fast
k
. Following the 
fast repair pathway, the number 2, 2,
( )fast fastn n t=
 is counting fragments prepared for the fast 
final repair process by a “delayed” first order kinetics process with the speed constant 1, fast
k
, 
the delay time ,r fast
t
. These fragments are removed by a second order process (2 fragments are 
linked together) with the repair constant 2, fastk . The slow repair pathway has the same structure 
with the number of fragments recruited for the slow repair-pathway 1, 1, ( )slow slown n t=  by a first 
order kinetics process with the speed constant 0,slowk  and the number of fragments 
2 , 2 , ( )slow slown n t=
 prepared for the slow final repair process by a “delayed” first order kinetics 
process (speed constant 1,slowk ; delay time ,r slowt ) and removed by second order repair (repair 
constant 2 , s lo wk ). The total number of free fragments (visible in the Comet tail) is calculated 
by: 
0 , ,( )Comet i fast i slow n
i
n n n n b= + + +∑
 (1) 
 
where nb  is the base line number of fragments that can be estimated along with the other 
parameters. All numbers of fragments are scaled to the percentage of DNA in tail (%DNA 
fragments in tail, corresponding to the experimental data). The induction-, production-  and 
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repair rates are given by the following system of ordinary (ODE) and delay differential 
equations (DDE):   
0
0, 0, 0
1,
0, 0 1, 1, ,
2, 2
1, 1, , 2, 2,
1,
0, 0 1, 1, ,
2,
1, 1,
( )
( )
( )
( )
cleav fast slow
fast
fast fast fast r fast
fast
fast fast r fast fast fast
slow
slow slow slow r slow
slow
slow s
dn k R k k n
dt
dn
k n k n t t
dt
dn
k n t t k n
dt
dn
k n k n t t
dt
dn
k n
dt
= − + ⋅
= − −
= − −
= − −
=
2
, 2, 2,( )low r slow slow slowt t k n− −
 (2) 
 
With the initial conditions: 
 
0 2, 2,(0) (0) (0) 0fast slown n n= = =
 
and 
1, 1,( 0) ( 0) 0fast slown t n t< = < =
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Additional File 2: Absolute values of median tail intensity (% DNA in tail), comet assay 
(%; 95%CI). T0, T15, T30, etc. indicate the time-points in minutes after completion of 
radiation treatment
  
Time-points 
% DNA in tail  
(95%CI) 
p-value 
T0 4.31  
T15 15.11 (11.98 – 18.24) p=0.001 
T30 15.55 (12.25 – 18.84) p=0.001 
T60 11.42 (8.79 – 14.04) p<0.001 
T120 6.78 (3.29 – 10.27) p=0.172 
T360 5.55 (3.27 – 7.82) p=0.185 
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